UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): ~~May~~June 2315, 2023

BIONIK LABORATORIES CORP.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		000-54717		27-1340346
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File Number)		(IRS Employer Identification No.)

80 Coolidge Hill Road

Watertown, MA

02472

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 926-4800

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Not applicable		Not applicable		Not applicable

Item 7.01

Regulation FD Disclosure.

On ~~May~~June 2315, 2023, Bionik Laboratories Corp. (the “Company”) issued a press release to announce that it ~~has~~continues ~~experienced~~to agrow ~~significant increase in patient volume at~~ its ~~rehabilitation~~partnership ~~center,~~with ~~Tower~~Lifepoint ~~Physical Therapy & Rehab~~Health, with infour ~~Clermont,~~new ~~Florida.~~installations ~~During~~of the ~~first~~InMotion® ~~eight~~ARM ~~months~~robotic ~~since~~device ~~the~~in ~~acquisition of~~Phoenix, ~~the~~Arizona, ~~center was finalized~~Sacramento, ~~the Company has more than doubled its patient count~~California, ~~increased revenue~~Brownsburg, Indiana, and ~~has seen an increase in the amount of patient hours logged on its InMotion® robotic devices on-site at the clinic~~Louisville, ~~a new offering that has brought more patients in the door for rehabilitation services~~Kentucky.

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

Item 9.01

Financial Statements and Exhibits.

Exhibit		Description
99.1		Press release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: ~~May~~June 2315, 2023

	BIONIK LABORATORIES CORP.

	By:	/s/ Rich Russo Jr.
	Name:	Rich Russo Jr.
	Title:	Chief Executive Officer

Filing Compare · Bionik Laboratories Corp.